PTSD

>

Latest News

Otsuka and Lundbeck Will Face Scrutiny Over Investigational PTSD Therapy at July 18 FDA AdComm Meeting
Otsuka and Lundbeck Will Face Scrutiny Over Investigational PTSD Therapy at July 18 FDA AdComm Meeting

July 17th 2025

FDA's Psychopharmacologic Drugs Advisory Committee will evaluate the novel brexpiprazole/sertraline combination, weighing efficacy against existing therapies amid mixed trial results.

Investigational Rapid-Acting PTSD Medication Awarded FDA Breakthrough Therapy Status / image credit ©Feng Yu/stock.adobe.com
Investigational Rapid-Acting PTSD Medication Awarded FDA Breakthrough Therapy Status: Transcend Therapeutics Update

July 10th 2025

FDA to Convene Advisory Committee on Brexpiprazole-Sertraline for Adult PTSD / image credit ©Tada Images - stock.adobe.com
FDA to Convene Advisory Committee on Brexpiprazole-Sertraline for Adult PTSD

January 10th 2025

sNDA for Brexpiprazole/Sertraline Combination for PTSD Submitted for FDA Review / image credit FDA logo: ©Araki Illustrations/stock.adobe.com
sNDA for Brexpiprazole/Sertraline Combination for PTSD Submitted for FDA Review

May 3rd 2024

More News

Optimizing PTSD Treatment: The Role of Brexpiprazole and Sertraline in Future Guidelines

Optimizing PTSD Treatment: The Role of Brexpiprazole and Sertraline in Future Guidelines

Lori Davis, MD;Sydney Jennings
February 3rd 2025

Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.

©MJH Life Sciences

PTSD Treatment Advancements: Brexpiprazole-Sertraline Offers New Hope in Phase 3 Trial

Lori Davis, MD;Sydney Jennings
January 29th 2025

Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.

© 2025 MJH Life Sciences

All rights reserved.